65610 Federal Register / Vol. 69, No. 219 / Monday, November 15, 2004 / Notices 

engineered commensal bacteria 

compositions that secrete HIV 

infectivity interfering peptides with the 

aid of co-expressed translocation 

mediators such as HylB, HylD or tolC

gene products. The bacteria can be, for 

example, Escherichia coli and are 

preferably those that colonize the 

gastrointestinal or genitourinary tracts. 

The secreted anti-HIV peptide can be a 

functional inhibitory fragment from the 

C-terminus of HIV, SHIV or SIV, or an 

inhibitory peptide derived from the Nterminus receptor-binding domain of 

SIV gp41, HIV–1 gp41, or HIV–2 gp41. 

The secreted anti-HIV peptide can also 

be a peptide from the allosteric domain 

of gp120, an extracellular loop of CCR5, 

an anti-CD4 immunoglobulin, a mimetic 

of CD4, an alpha-defensin or thetadefensin, a CD38 fragment homologous 

to the V3 loop of gp120, polphemusin 

II (a CXCR4 antagonist), a RANTES 

peptide that binds to CCR5 or an HIV 

surface binding peptide such as 

cyanovirin. 

Method of Assessing Ischemia in a 

Patient 

Steven Warach, Lawrence Latour 

(NINDS). 

U.S. Provisional Application No. 60/

381,611 filed 17 Mar 2002 (DHHS 

Reference No. E–082–2002/0–US–01); 

PCT Application No. PCT/US03/

15368 filed 16 May 2003 (DHHS 

Reference No. E–082–2002/0–PCT–

02). 

Licensing Contact: Michael Shmilovich; 

301/435–5019; 

shmilovm@mail.nih.gov.

Hyperintense acute reperfusion 

marker (HARM) is well correlated with 

reperfusion and is a precursor to or 

concomitant with reperfusion injury. 

The inventors have developed a novel 

technique of assessing injuries 

associated with ischemia, stroke, or 

reperfusion injury in a patient by 

administering a contract agent to the 

patient, acquiring a fluid-attenuated 

inversion-recovery (FLAIR) image, and 

observing the presence or absence of 

HARM on the acquired image. The 

technique can also be used to determine 

the effectiveness of a therapeutic 

protocol for the treatment or prevention 

of reperfusion injury in a patient that 

has previously suffered an ischemic 

event. 

This research has been described, in 

part, in Latour et al., ‘‘Early Blood-Brain 

Barrier Disruption in Human Focal 

Brain Ischemia,’’ Ann. Neurol. 2004 

56:568–477.

Dated: November 4, 2004. 

Steven M. Ferguson, 

Director, Division of Technology Development 

and Transfer, Office of Technology Transfer, 

National Institutes of Health.

[FR Doc. 04–25278 Filed 11–12–04; 8:45 am] 

BILLING CODE 4140–01–P

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

Government-Owned Inventions; 

Availability for Licensing

AGENCY: National Institutes of Health, 

Public Health Service, DHHS.

ACTION: Notice.

SUMMARY: The inventions listed below 

are owned by an agency of the U.S. 

Government and are available for 

licensing in the U.S. in accordance with 

35 U.S.C. 207 to achieve expeditious 

commercialization of results of 

federally-funded research and 

development. Foreign patent 

applications are filed on selected 

inventions to extend market coverage 

for companies and may also be available 

for licensing.

ADDRESSES: Licensing information and 

copies of the U.S. patent applications 

listed below may be obtained by writing 

to the indicated licensing contact at the 

Office of Technology Transfer, National 

Institutes of Health, 6011 Executive 

Boulevard, Suite 325, Rockville, 

Maryland 20852–3804; telephone: 301/

496–7057; fax: 301/402–0220. A signed 

Confidential Disclosure Agreement will 

be required to receive copies of the 

patent applications. 

Infectious Clone of Human Parvovirus 

B19 and Methods of Use 

Ning Zhi et al. (NHLBI). 

U.S. Patent Application No. 10/887,770 

filed 09 Jul 2004 (DHHS Reference 

No.E–178–2004/0–US–01 and 

corresponding Canadian patent 

application (DHHS Reference No. E–

178–2004/0–CA–02). 

Licensing Contact: Susan Ano; 301/435–

5515; anos@mail.nih.gov.

This technology described in this 

patent application relates the first 

reported infectious human parvovirus 

B19 clone, methods of cloning the 

parvovirus B19 genome as well as other 

viral genomes that have secondary DNA 

structures that are unstable in bacterial 

cells. The infectious clone and methods 

of producing the same would be useful 

in producing infectious virus, which 

can in turn be used, among other things, 

to identify and develop therapeutic 

agents for treatment and/or prevention 

of human parvovirus B19 infections. 

The infectious parvovirus B19 clone is 

also available for licensing. Additional 

information about this invention can be 

found in Virology 2004, 318(1), 142–

152. 

Immunogenic Compositions for 

Eradication of Latent HIV 

Genoveffa Franchini et al. (NCI). 

U.S. Provisional Application No. 60/

536,467 filed 13 Jan 2004 (DHHS 

Reference No. E–072–2004/0–US–01); 

U.S. Provisional Application No. 60/

536,976 filed 16 Jan 2004 (DHHS 

Reference No. E–072–2004/1–US–01). 

Licensing Contact: Susan Ano; 301/435–

5515; anos@mail.nih.gov.

HIV infects CD4+ cells and, after 

incorporation of the viral genome into 

the host genome, can either produce 

infectious virus or remain latent. HIV 

that is latent presents a challenge for 

complete removal of the virus in 

infected individuals and is becoming an 

increasingly important consideration in 

the identification of potential 

therapeutics or treatment regimens. This 

patent application describes 

immunogenic compositions based on 

inhibiting the function of p28TEV

protein, the first protein expressed 

during HIV infection, for treatment of 

latent HIV infection. Specifically, these 

compositions include the p28TEV

polypeptide, a polypeptide with 

significant sequence homology to 

p28TEV, or immunogenic fragments of 

these polypeptides. Additional 

compositions include antibodies and 

other compounds that act to inhibit 

p28TEV activity. This technology can 

also be utilized to detect latent HIV in 

biological samples. These compositions 

and methods offer a potential solution 

for complete virus eradication in 

therapeutic treatment of HIV infected 

individuals. 

Accelerated Vaccination Strategies To 

Provide Protection Against Viral 

Infections 

Gary J. Nabel et al. (NIAID). 

U.S. Provisional Application No. 60/

491,933 filed 01 Aug 2003 (DHHS 

Reference No. E–317–2003/0–US–01); 

PCT Application filed on 01 Aug 2004 

(DHHS Reference No. E–317–2003/0-

PCT–02). 

Licensing Contact: Susan Ano; 301/435–

5515; anos@mail.nih.gov.

The technology described in this 

patent application relates to 

recombinant viruses for use as vaccines. 

These viruses contain a single or 

plurality of sequences encoding 

antigens from pathogenic viruses

Federal Register / Vol. 69, No. 219 / Monday, November 15, 2004 / Notices 65611

heterologous to the recombinant virus. 

The antigenic sequences from pathogens 

such as influenza, RSV, measles, HPV, 

Epstein-Barr, Lassa, Polio, West Nile, 

Dengue, HIV–1 and 2, HTLV, herpes 

simplex virus, hepatitis viruses A, B, C, 

D, and E, Marburg, Ebola, and SARS are 

inserted into non-essential regions of 

either replication-competent or 

replication-defective adenovirus, adenoassociated virus (AAV), SV40 virus, 

herpes simplex virus, or vaccinia virus 

vectors that retain elements necessary 

for infectivity but are devoid of any 

pathogenic sequence elements. In these 

recombinant viruses, the antigenic 

sequences are operably linked to viral 

control elements. Thus, these 

recombinant viruses are capable of 

infecting a host and mounting an 

immune response specific to a given 

virus(es) without eliciting 

pathogenicity. In addition to the above, 

the technology also describes methods 

of accelerated pre-exposure or postexposure vaccination comprising singledose administration. The attractive 

features of this invention include the 

broad applicability of the recombinant 

viruses against a number of common 

pathogens and the potential of using 

them against other emergent infectious 

viruses; the ability of the vaccines to 

stimulate both cellular and humoral 

immune responses in humans and other 

hosts; and the ease of administration in 

single dose form via a number of routes. 

This technology is now available for 

licensing. Some fields of use may not be 

available.

Dated: November 9, 2004. 

Steven M. Ferguson, 

Director, Division of Technology Development 

and Transfer, Office of Technology Transfer, 

National Institutes of Health.

[FR Doc. 04–25279 Filed 11–12–04; 8:45 am] 

BILLING CODE 4140–01–P

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

National Cancer Institute; Notice of 

Meeting 

Pursuant to section 10(d) of the 

Federal Advisory Committee Act, as 

amended (5 U.S.C. Appendix 2), notice 

is hereby given of the meeting of the 

National Cancer Advisory Board. 

The meeting will be open to the 

public as indicated below, with 

attendance limited to space available. 

Individuals who plan to attend and 

need special assistance, such as sign 

language interpretation or other 

reasonable accommodations, should 

notify the Contact Person listed below 

in advance of the meeting. 

A portion of the meeting will be 

closed to the public in accordance with 

the provision set forth in section 

552b(6), as amended. The discussion 

could disclose personal information 

concerning NCI Staff and/or its 

contractors, the disclosure of which 

would constitute a clearly unwarranted 

invasion of personal privacy.

Name of Committee: National Cancer 

Advisory Board. 

Open: November 30, 2004, 8:30 a.m. to 

5:30 p.m. 

Agenda: Program reports and 

presentations; Business of the Board. 

Place: Name Cancer Institute, 9000 

Rockville Pike, Building 31, C Wing, 6th 

Floor, Conference Room 10, Bethesda, MD 

20892. 

Contact Person: Dr. Paulette S. Gray, 

Executive Secretary, National Cancer 

Institute, National Institutes of Health, 6116 

Executive Boulevard, 8th Floor, Room 8001, 

Bethesda, MD 20892–8327, (301) 496–5147.

Name of Committee: National Cancer 

Advisory Board. 

Open: December 1, 2004, 8:30 a.m. to 10:30 

a.m. 

Agenda: Program reports and 

presentations; Business of the Board. 

Contact Person: Dr. Paulette S. Gray, 

Executive Secretary, National Cancer 

Institute, National Institutes of Health, 6116 

Executive Boulevard, 8th Floor, Room 8001, 

Bethesda, MD 20892–8327, (301) 496–5147.

Name of Committee: National Cancer 

Advisory Board. 

Closed: December 1, 2004, 10:30 a.m. to 

adjournment. 

Agenda: Review intramural program site 

visit outcomes; Discussion of confidential 

personnel issues. 

Contact Person: Dr. Paulette S. Gray, 

Executive Secretary, National Cancer 

Institute, National Institutes of Health, 6116 

Executive Boulevard, 8th Floor, Room 8001, 

Bethesda, MD 20892–8327, (301) 496–5147.

Any interested person may file written 

comments with the committee by forwarding 

the statement to the Contact Person listed on 

this notice. The statement should include the 

name, address, telephone number and when 

applicable, the business or professional 

affiliation of the interested person. 

Information is also available on the 

Institute’s/Center’s home page: 

deainfo.nci.nih.gov/advisory/ncab.htm,

where an agenda and any additional 

information for the meeting will be posted 

when available.

(Catalogue of Federal Domestic Assistance 

Program Nos. 93.392, Cancer Construction; 

93.393, Cancer Cause and Prevention 

Research; 93.394, Cancer Detection and 

Diagnosis Research; 93.395, Cancer 

Treatment Research; 93.396, Cancer Biology 

Research; 93.397, Cancer Centers Support; 

93.398, Cancer Research Manpower; 93.399, 

Cancer Control, National Institutes of Health, 

HHS)

Dated: November 5, 2004. 

LaVerne Y. Stringfield, 

Director, Office of Federal Advisory 

Committee Policy.

[FR Doc. 04–25271 Filed 11–12–04; 8:45 am] 

BILLING CODE 4140–01–M

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

National Institute of Diabetes and 

Digestive and Kidney Diseases; Notice 

of Closed Meetings 

Pursuant to section 10(d) of the 

Federal Advisory Committee Act, as 

amended (5 U.S.C. Appendix 2), notice 

is hereby given of the following 

meetings. 

The meetings will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), Title 5 U.S.C., 

as amended. The grant applications and 

the discussions could disclose 

confidential trade secrets or commercial 

property such as patentable material, 

and personal information concerning 

individuals associated with the grant 

applications, the disclosure of which 

would constitute a clearly unwarranted 

invasion of personal privacy.

Name of Committee: National Institute of 

Diabetes and Digestive and Kidney Diseases 

Special Emphasis Panel, Urinary Infection. 

Date: December 7, 2004. 

Time: 8 a.m. to 5 p.m. 

Agenda: To reveiw and evaluate grant 

applications. 

Place: Courtyard By Marriott, 2899 

Jefferson Davis Highway, Arlington, VA 

22202. 

Contact Person: Maxine A. Lesniak, MPH, 

Scientific Review Administrator, Review 

Branch, DEA, NIDDK, National Institutes of 

Health, Room 756, 6707 Democracy 

Boulevard, Bethesda, MD 20892–5452, (301) 

594–7792, lesniakm@extra.niddk.nih.gov.

Name of Committee: National Institute of 

Diabetes and Digestive and Kidney Diseases 

Special Emphasis Panel, Diabetes. 

Date: December 13, 2004. 

Time: 8 a.m. to 5 p.m. 

Agenda: To reveiw and evaluate grant 

applications. 

Place: Hyatt Regency—Crystal City, 2799 

Jefferson Davis Highway, Arlington, VA 

22202. 

Contact Person: Maxine A. Lesniak, MPH, 

Scientific Review Administrator, Review 

Branch, DEA, NIDDK, National Institutes of 

Health, Room 756, 6707 Democracy 

Boulevard, Bethesda, MD 20892–5452, (301) 

594–7792, lesniakm@extra.niddk.nih.gov.

Name of Committee: National Institute of 

Diabetes and Digestive and Kidney Diseases 

Special Emphasis Panel, Clinical Studies of 

Kidney Disease. 

Date: December 16, 2004.